Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

FDA accepts IND for phase I trial of JCAR-017 for relapsed/refractory B-cell NHL

June 30, 2015

rF-GM-CSF and rF-TRICOM are safe is patients with bladder carcinoma

June 30, 2015

Patrys awards Chinese license for cancer therapy PAT-SC1

June 30, 2015

Immunovaccine and Incyte collaborate to investigate combination of DPX-Survivac and epacadostat

June 30, 2015

Novogen advances anisina towards clinic

June 29, 2015

Calithera selects oral arginase inhibitor CB-1158 as immuno-oncology clinical candidate

June 26, 2015

Western Oncolytics closes financing round to advance cancer immunotherapy

June 26, 2015

Encouraging first-in-human data obtained with BI-836826 in CLL

June 25, 2015

Vaxil's ImMucin designated FDA orphan drug for multiple myeloma

June 23, 2015

New round of funding to support Batu Biologics' development of ValloVax

June 23, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 9, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...